Drug intelligence / Profile preview

LipovaxinS4-EAH

Development stage: Unknown
Lead developer: Bio Farma
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

LipovaxinS4-EAH is a liposomal protein subunit vaccine candidate developed by PT Bio Farma for the prevention of tuberculosis. The vaccine utilizes a liposome-based delivery system to present recombinant *Mycobacterium tuberculosis* antigens to the immune system, aiming to induce protective cellular and humoral immunity. It is currently being evaluated in Phase I clinical trials in Indonesia to determine its safety, tolerability, and immunogenicity in healthy adult populations. The formulation typically involves a two-dose regimen administered via injection.

Brand names: Lipovaxin
Other names: Lipovaxin Tuberculosis Vaccine

Targets

Ag85C (Antigen 85C)ESAT-6 (Early secretory antigenic target 6)

Beyond the preview

Go deeper on LipovaxinS4-EAH.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LipovaxinS4-EAH.

Explore the full profile